Current and planned vaccine manufacturing in Africa: Results from a joint assessment by Africa CDC, CHAI, and PATH

Study methodology
Between December 2022 and March 2023, a collaborative team with representatives from Africa CDC, CHAI, and PATH engaged vaccine manufacturers across Africa on their current and planned production Current and planned vaccine manufacturing in Africa Results from a joint assessment by Africa CDC, CHAI, and PATH capacity, technical and commercial capabilities, and supporting functions (such as regulatory and finance).

We engaged 19 manufacturers in total, including all manufacturers with commercial scale production capacity as well as a number of early-stage projects. We also engaged with a variety of originator companies outside of Africa interested in technology transfers to African vaccine manufacturers to understand where they see opportunities, challenges, and considerations for collaboration.
When possible, we calculated capacity estimates in a range from minimum to maximum, due to manufacturer uncertainty about antigens and number of doses per container. Actual annual capacity may vary significantly.

We used the year 2030 as a benchmark for vaccine demand.
We also reference the year 2040 to reflect the Partnerships for African Vaccine Manufacturing (PAVM) Framework for Action, which sets the goal of manufacturing 60 percent of Africa’s routine immunization needs on the continent by 2040.2

Caveats
Other aspects of the vaccine manufacturing ecosystem that are critical success factors were not covered by this research, including infrastructure development and improvement, national regulatory authority strengthening, and market shaping, among others.